Home - Products - Others - Other Targets - 7,4-Dihydroxyhomoisoflavanone

7,4-Dihydroxyhomoisoflavanone

CAS No. 1178893-64-5

7,4-Dihydroxyhomoisoflavanone( —— )

Catalog No. M31309 CAS No. 1178893-64-5

(3R)-7,4’-Dihydrohomoisoflavanone, a natural compound, exhibits potent antibacterial properties against both S. aureus and methicillin-resistant Staphylococcus aureus (MRSA).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 603 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock

Biological Information

  • Product Name
    7,4-Dihydroxyhomoisoflavanone
  • Note
    Research use only, not for human use.
  • Brief Description
    (3R)-7,4’-Dihydrohomoisoflavanone, a natural compound, exhibits potent antibacterial properties against both S. aureus and methicillin-resistant Staphylococcus aureus (MRSA).
  • Description
    (3R)-7,4’-Dihydrohomoisoflavanone, a natural compound, exhibits potent antibacterial properties against both S. aureus and methicillin-resistant Staphylococcus aureus (MRSA).
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1178893-64-5
  • Formula Weight
    270.3
  • Molecular Formula
    C16H14O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • DL-3-Phenyllactic ac...

    3-Phenyllactic acid (PhLA) is a broad spectrum antimicrobial compound active against bacteria and fungi.

  • Norsanguinarine

    Norsanguinarine has antifungal activity, it exhibits 100 % inhibition of A. brassicicola and C. maculans at 1000 ppm whereas. It shows significant cytotoxic activities (ED (50) values < 4 microg/ml) against P-388, KB16, A549, and HT-29 cell lines.

  • RC-3095 (TFA)

    RC-3095 is a bombesin/gastrin-releasing peptide (BN/GRP) antagonist with potential anticancer activity.